Related Experiment Videos
Effects of lithium treatment on hypothalamic-pituitary-thyroid axis: a longitudinal study
G Lombardi1, N Panza, B Biondi
1Dipartimento di Endocrinologia, Università di Napoli, Italy.
Journal of Endocrinological Investigation
|April 1, 1993
Summary
Lithium carbonate treatment frequently causes subclinical hypothyroidism in bipolar patients, indicated by elevated thyroid-stimulating hormone (TSH) levels. Prophylactic thyroxine replacement is recommended to prevent hypothyroidism and goiter during lithium therapy.
Area of Science:
- Endocrinology
- Psychiatry
- Pharmacology
Background:
- Lithium carbonate is a standard treatment for bipolar disorder.
- Lithium is known to cause thyroid dysfunction.
- Longitudinal data on lithium's impact on thyroid function is limited.
Purpose of the Study:
- To investigate thyroid function during 12 months of lithium treatment in euthymic bipolar patients.
- To assess the prevalence of subclinical hypothyroidism and hypothalamic-pituitary-thyroid (HPT) axis changes.
- To evaluate the long-term effects and recommend preventive strategies.
Main Methods:
- Longitudinal study of 12 euthymic bipolar patients over 12-24 months.
- Monitoring of basal and TRH-stimulated TSH, T3, T4, FT3, and FT4 levels.
- Assessment for thyroid antibodies and goiter development.
Main Results:
- Significant increases in mean basal and TRH-stimulated TSH levels were observed during lithium therapy.
- 10/12 patients showed elevated basal TSH, and 11/12 showed elevated TRH-stimulated TSH.
- Two patients developed nodular goiter; plasma thyroid hormone levels remained stable. HPT axis impairment was mostly transitory.
Conclusions:
- Subclinical hypothyroidism is more common during lithium therapy than previously suggested.
- Thyroxine replacement is advisable to prevent lithium-induced subclinical hypothyroidism and goiter.